Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
18:47:00 EDT Mon 30 Jun 2025
Enter Symbol
or Name
USA
CA



Q:MNKD - MANNKIND CORPORATION - https://www.mannkindcorp.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
MNKD - Q1.43.69·3.850.73.74-0.02-0.53,315.611,7477,2373.76  3.7806  3.657.62  3.6318:03:35Jun 0915 min RT 2¢

Recent Trades - Last 10 of 7237
Time ETExPriceChangeVolume
18:03:35Q3.780.022
17:50:04Q3.770.0130
17:46:51Q3.770.011
17:11:03Q3.76 4
17:05:08Q3.76930.00931
16:55:52Q3.770.011
16:53:12Q3.76990.00991
16:50:38Q3.69-0.0715
16:50:16Q3.6901-0.0699700
16:38:31Q3.770.011

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-06-09 16:05U:MNKDNews ReleaseMannKind to Highlight Data from Recent Pediatric and Adult Studies of Inhaled Insulin (Afrezza(TM)) at American Diabetes Association's 85th Scientific Sessions in Chicago, June 20-23
2025-05-27 09:15U:MNKDNews ReleaseINDYCAR Driver Conor Daly To Share His Personal Diabetes Story and Race Go-Karts With Detroit Area Youth On Thursday, May 29
2025-05-13 16:05U:MNKDNews ReleaseMannKind to Present at Upcoming Investor Conferences
2025-05-08 08:05U:MNKDNews ReleaseMannKind Corporation Reports First Quarter 2025 Financial Results and Provides Business Update
2025-05-01 16:05U:MNKDNews ReleaseMannKind Corporation to Hold 2025 First Quarter Financial Results Conference Call on May 8, 2025
2025-04-07 12:30U:MNKDNews ReleaseMannKind Teams Up with Juncos Hollinger Racing (JHR) Driver Conor Daly to Drive Awareness of Diabetes and Innovative Treatment Options
2025-03-10 06:05U:MNKDNews ReleaseMannKind Showcases Efficacy, Safety, and Mealtime Control Data from Recent Pediatric and Adult Studies of Afrezza(TM) at the ATTD Conference, March 19-22
2025-02-26 16:05U:MNKDNews ReleaseMannKind Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
2025-02-19 16:05U:MNKDNews ReleaseMannKind Corporation to Hold 2024 Fourth Quarter and Full Year Financial Results Conference Call on February 26, 2025
2025-02-06 16:05U:MNKDNews ReleaseMannKind to Present at Upcoming Investor Conferences
2025-01-06 16:30U:MNKDNews ReleaseMannKind Expands Executive Leadership Team
2024-12-18 07:00U:MNKDNews ReleaseMannKind Corporation Announces Exchange of Convertible Notes for Stock and Cash
2024-12-16 06:05U:MNKDNews ReleaseMannKind Announces Six-Month Results From Phase 3 INHALE-1 Pediatric Diabetes Trial Utilizing Inhaled Insulin (Afrezza(TM))
2024-12-11 06:00U:MNKDNews ReleaseCDSCO Approves Afrezza(TM) (insulin human) Inhalation Powder in India
2024-11-07 16:02U:MNKDNews ReleaseMannKind Corporation Reports 2024 Third Quarter Financial Results and Provides Business Update
2024-11-05 16:15U:MNKDNews ReleaseMannKind to Present at 2024 UBS Healthcare Conference
2024-11-04 06:05U:MNKDNews ReleaseMannKind Successfully Completes Phase 1 Trial of Nintedanib DPI for Pulmonary Fibrotic Diseases
2024-10-31 16:05U:MNKDNews ReleaseMannKind Corporation to Hold 2024 Third Quarter Financial Results Conference Call on November 7, 2024
2024-09-30 06:00U:MNKDNews ReleaseMore Adults With Type 1 Diabetes Achieved A1C Goal (<7%) After Switching From Multiple Daily Insulin Injections or Automated Pumps to Inhaled Insulin (Afrezza(TM))
2024-09-18 06:15U:MNKDNews ReleaseMannKind Announces Clearance from PMDA to Initiate Phase 3 Clinical Trial (ICoN-1) in Japan Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease